A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Melanoma treatment options are expanding, but resistance and ineligibility for current therapies necessitate novel approaches.
• BH3 mimetics, which mimic pro-apoptotic BCL2 proteins, have shown clinical success.
• The combination of venetoclax (ABT-199) and azacitidine is effective in acute myelogenous leukemia.

Purpose of the Study:

• To evaluate the efficacy of combining BH3 mimetics with azacitidine in various human melanoma subtypes.
• To identify specific BCL2 family protein targets that enhance azacitidine's anti-melanoma effects.

Main Methods:

• Utilized fourteen human melanoma cell lines (cutaneous, mucosal, acral, uveal).
• Employed cell viability assays, BCL2 family knockdown models, live cell imaging, and sphere formation assays.
• Investigated combinations of BH3 mimetics with azacitidine.

Main Results:

• Combining MCL1 inhibition with azacitidine demonstrated significant pro-apoptotic effects across multiple melanoma cell lines.
• This combination reduced cell viability, proliferation, and sphere formation, while inducing apoptosis.
• The combination proved highly effective in reducing cell viability in rare mucosal and uveal melanoma subtypes.

Conclusions:

• The combination of MCL1 inhibition and azacitidine is a promising therapeutic strategy for melanoma.
• This approach warrants further investigation in clinical trials, particularly for patients with limited treatment options.
• The findings highlight potential for treating rare melanoma subtypes effectively.